Celltrion's biosimilar omalizumab, branded as Omilclo, is making significant strides in the European market, now available in 26 countries. As of July, it is estimated to hold over 90% market share in Spain, with sales in Italy also exceeding initial business targets.
On September 10, Celltrion announced its participation in the '2026 European Respiratory Society (ERS) Conference' held in Barcelona from September 5 to 9, aimed at expanding Omilclo's presence in key European markets. The ERS is the largest respiratory conference in Europe, attracting around 20,000 healthcare professionals and researchers annually to share the latest research findings and treatment strategies.
Following the launch of Omilclo in Europe at the end of last year, Celltrion accelerated its market expansion by introducing a 300mg formulation in August. At the conference, the company showcased Omilclo's competitive advantages under the theme 'Similar, but Different' at its independent booth.
Omilclo is available in various dosages, including 75mg, 150mg, and 300mg, and offers multiple delivery devices such as pre-filled syringes (PFS) and auto-injectors (AI), providing flexibility based on patient conditions and administration settings. The product's storage stability, convenience, latex-free composition, and reliable supply capabilities were also highlighted as key competitive strengths.
A Celltrion representative stated, "Based on the initial successes observed in key markets like Spain and Italy, we plan to expand participation in country-specific tenders and strengthen connections with healthcare institutions and professionals. This will enable us to implement sales and marketing strategies tailored to the characteristics of each market and spread Omilclo's success across Europe."
On the second day of the conference, an 'Expert Insights' event focused on the clinical significance of omalizumab treatment and its practical applications in healthcare settings. Renowned asthma expert Professor Roland Bull from Mainz University in Germany participated as a speaker, sharing insights on the clinical utility and long-term safety of omalizumab in allergic asthma patients, as well as the role of biosimilars in treating respiratory diseases and future trends.
Celltrion aims to convert the interest generated among healthcare professionals at the ERS into increased prescriptions and sales by enhancing academic, sales, and marketing activities tailored to each country's market environment. The company plans to continue its existing sales efforts focused on tendering institutions while expanding its network with healthcare institutions and professionals that influence product purchases and prescriptions.
Additionally, Celltrion is launching an open innovation program in collaboration with the Kobe Biomedical Innovation Cluster (KBIC) in Japan, aimed at supporting the global market entry of Korean and Japanese biotech startups. This initiative seeks to combine Japan's basic research capabilities with Celltrion's experience in drug development, production, and commercialization to identify promising technologies and achieve tangible business outcomes through joint research and the establishment of next-generation pipelines.
On September 10, Celltrion announced its participation in the '2026 European Respiratory Society (ERS) Conference' held in Barcelona from September 5 to 9, aimed at expanding Omilclo's presence in key European markets. The ERS is the largest respiratory conference in Europe, attracting around 20,000 healthcare professionals and researchers annually to share the latest research findings and treatment strategies.
Following the launch of Omilclo in Europe at the end of last year, Celltrion accelerated its market expansion by introducing a 300mg formulation in August. At the conference, the company showcased Omilclo's competitive advantages under the theme 'Similar, but Different' at its independent booth.
Omilclo is available in various dosages, including 75mg, 150mg, and 300mg, and offers multiple delivery devices such as pre-filled syringes (PFS) and auto-injectors (AI), providing flexibility based on patient conditions and administration settings. The product's storage stability, convenience, latex-free composition, and reliable supply capabilities were also highlighted as key competitive strengths.
A Celltrion representative stated, "Based on the initial successes observed in key markets like Spain and Italy, we plan to expand participation in country-specific tenders and strengthen connections with healthcare institutions and professionals. This will enable us to implement sales and marketing strategies tailored to the characteristics of each market and spread Omilclo's success across Europe."
On the second day of the conference, an 'Expert Insights' event focused on the clinical significance of omalizumab treatment and its practical applications in healthcare settings. Renowned asthma expert Professor Roland Bull from Mainz University in Germany participated as a speaker, sharing insights on the clinical utility and long-term safety of omalizumab in allergic asthma patients, as well as the role of biosimilars in treating respiratory diseases and future trends.
Celltrion aims to convert the interest generated among healthcare professionals at the ERS into increased prescriptions and sales by enhancing academic, sales, and marketing activities tailored to each country's market environment. The company plans to continue its existing sales efforts focused on tendering institutions while expanding its network with healthcare institutions and professionals that influence product purchases and prescriptions.
Additionally, Celltrion is launching an open innovation program in collaboration with the Kobe Biomedical Innovation Cluster (KBIC) in Japan, aimed at supporting the global market entry of Korean and Japanese biotech startups. This initiative seeks to combine Japan's basic research capabilities with Celltrion's experience in drug development, production, and commercialization to identify promising technologies and achieve tangible business outcomes through joint research and the establishment of next-generation pipelines.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.